LAS VEGAS, June 22, 2018 /PRNewswire/ --

FN Media Group Presents Microcapspeculators.com News Commentary 

This is set to be the fifth consecutive quarter in which at least ten biotech companies have made it to market on U.S. exchanges and have raised at least a billion dollars in aggregate.

This is a great time to be raising money. The Nasdaq Biotech Index is well off of its 2015 highs, but is still up nearly 40 percent from its post-pop lows. Meanwhile, investors seem more confident than ever to invest in promising small biotech companies.

These biotech companies are making great progress: Propanc BioPharma, Inc. (OTC:PPCB), Verastem, Inc. (NASDAQ:VSTM), NeuroMetrix, Inc. (NASDAQ:NURO), Caladrius Biosciences, Inc. (NASDAQ:CLBS), Stemline Therapeutics, Inc. (NASDAQ:STML).

Propanc BioPharma, Inc. (OTCQB:PPCB)

Market Cap: 2.52M, current share price: $0.06 

Propanc BioPharma, Inc. is a clinical stage biopharmaceutical company focusing on

development of new and proprietary treatments for cancer patients suffering from solid tumors

such as pancreatic, ovarian and colorectal cancers, recently announced it had completed a

scientific advice meeting with the MHRA in reference to the company's lead product PRP which

has been designated as a Orphan Drug by the FDA for Pancreatic Cancer. Additionally the

company went through a number of topics regarding the Clinical Trial Application for PRP, and

the first in human studies that the company plans to conduct in the UK for its lead product PRP.

PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor

recurrence and metastasis, the main cause of patient death from cancer. PRP, is a novel, patented,

formulation consisting of two proenzymes mixed in a synergetic ratio that targets solid tumors.

Verastem, Inc. (NASDAQ:VSTM)

Market Cap: 636.32M, current share price: $8.67 

Verastem, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. Its defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. The company also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with hematologic cancers through the dual inhibition of PI3K delta and gamma. Its duvelisib is in Phase 3 randomized and late-and mid-stage clinical trials for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with double-refractory indolent non-Hodgkin lymphoma.

NeuroMetrix, Inc. (NASDAQ:NURO)

Market Cap: 10.88M, current share price: $1.48 

NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain.

Caladrius Biosciences, Inc. (NASDAQ:CLBS)

Market Cap: 63.25M, current share price: $6.61 

Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. Its business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products.

Stemline Therapeutics, Inc. (NASDAQ:STML)

Market Cap: 505.98M, current share price: $17.75 

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trial to attack brain cancer. The company's preclinical pipeline products include SL-501, a next generation IL-3R-targeted therapy; SL-101, a single chain monoclonal antibody fragment for the treatment of hematologic cancers; and SL-901, a small molecule kinase inhibitor.

DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM,) and its online brand FinancialNewsMedia.com, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks included herein by MS. FNM was not compensated by any public company mentioned herein to disseminate this press release on behalf of MS.

MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.  ACR Communication, LLC has been compensated one thousand dollars cash for this article and seventy-nine thousand two hundred dollars total by Regal Consulting, LLC, for PPCB.  PPCB and Regal Consulting, LLC were given an opportunity to edit information included in this article.  This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information.  ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article's distribution.  

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.

Contact Information:
Microcap Speculators
info@microcapspecualtors.com
+1-702-720-6310
http://microcapspeculators.com/

Media Contact
FN Media Group LLC
e-mail:  editor@financialnewsmedia.com
(954)345-0611

SOURCE Microcapspeculators.com